FindTrial
Sign In

Effect of PCSK9 inhibitors in patients with acute type A aortic dissection

Effect of PCSK9 inhibitors in patients with acute type A aortic dissection

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063602
Enrollment
Unknown
Registered
2022-09-13
Start date
2022-09-12
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Type A Aortic Dissection

Interventions

experimental group:subcutaneous injection of Evolocumab Injection

Sponsors

The First Affiliated Hospital of Shantou University Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.The patient voluntarily participates in the trial and signs an informed consent form; 2.The age = 20 years; 3.The physical condition allows subcutaneous injection of Evolocumab Injection(Repatha).

Exclusion criteria

Exclusion criteria: 1.Previous history includes secondary causes of hyperlipidemia or mixed dyslipidemia, such as nephrotic syndrome and hypothyroidism; 2. Lactating or pregnancy; 3. Previous history of coronary atherosclerotic heart disease or tumor disease; 4. Using PCSK9 inhibitors within 1 month before enrollment; 5. Participation in another clinical trial within 6 months; 6. Allergy to PCSK9 inhibitors.

Design outcomes

Primary

MeasureTime frame
30-day all-cause mortality;—

Countries

China

Contacts

Public ContactChen Yequn

The First Affiliated Hospital of Shantou University Medical College

962795057@qq.com+8675488905647

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026